Category
- PI3K/Akt/mTOR
- Epigenetics
- Methylation
- Immunology & Inflammation
- Protein Tyrosine Kinase
- Angiogenesis
- Apoptosis
- Autophagy
- ER stress & UPR
- JAK/STAT
- MAPK
- Cytoskeletal Signaling
- Cell Cycle
- TGF-beta/Smad
- DNA Damage/DNA Repair
- Stem Cells & Wnt
- Hippo
- Ubiquitin
- Neuronal Signaling
- NF-κB
- GPCR & G Protein
- Endocrinology & Hormones
- Transmembrane Transporters
- Metabolism
- Proteases
- Microbiology
- Others
Archives
MEK
Flavonoids Restore Platinum Drug Sensitivity to Ovarian Carcinoma Cells in a Phospho-ERK1/2-Dependent Fashion
17 views | Sep 15 2020
Yifat Koren Carmi et al. showed the potential of combining flavonoids with standard therapy to restore drug sensitivity to OC cells and overcomed TME-mediated platinum drug resistance. [Read the Full Post]
Proliferation of Vascular Smooth Muscle Cells under ox-LDL Is Regulated by Alismatis rhizoma Decoction via InhibitingERK1/2 and miR-17∼92a Cluster Activation
26 views | Sep 14 2020
Julian Shen et al. provided the multitarget mechanisms for application of AD in the treatment of atherosclerosis. [Read the Full Post]
Anti-inflammatory Effect of AZD6244 on Acrolein-Induced Neuroinflammation
17 views | Sep 10 2020
Wen-Chien Ho et al. suggested that ERK inhibition may be a neuroprotective target against acrolein-induced neuroinflammation in the CNS neurodegenerative diseases. [Read the Full Post]
Selumetinib for plexiform neurofibromas in neurofibromatosis type 1: a single-institution experience
35 views | Aug 09 2020
Vera Espírito Santo et al. showed that the drug was associated with clinical and radiological improvement. [Read the Full Post]
RAF dimer inhibition enhances the antitumor activity of MEK inhibitors in K-RAS mutant tumors
0 views | Jul 18 2020
Xi Yuan et al. supported a vertical inhibition strategy in which RAF dimer and MEKi are combined to target K-RAS-mutated cancers. [Read the Full Post]
A New Compound With Increased Antitumor Activity by Cotargeting MEK and Pim-1
63 views | Jun 30 2020
Yanan Li et al. uncovered a new MEK inhibitor KZ-02 with significantly enhanced antitumor activity by co-targeting MEK and Pim-1. [Read the Full Post]
MEK Inhibitors Combined With Programmed Cell death-1 Blockade Immunotherapy for Metastatic Uveal Melanoma: Is It Warranted?
60 views | Jun 30 2020
Anais Zanella et al. highlighted the need to evaluate the safety and efficacy of new treatment options such as MEKi and anti-PD-1 for mUM. [Read the Full Post]
Anti-Inflammatory Properties of Chemical Probes in Human Whole Blood: Focus on Prostaglandin E 2 Production
63 views | Jun 24 2020
Filip Bergqvist et al. deployed a semi-high throughput and robust methodology to investigate anti-inflammatory properties of new chemical probes. [Read the Full Post]
RAF Dimer Inhibition Enhances the Antitumor Activity of MEK Inhibitors in K-RAS Mutant Tumors
122 views | Jun 20 2020
Xi Yuan et al. supported a vertical inhibition strategy in which RAF dimer and MEKi are combined to target K-RAS-mutated cancers, and have led to a Phase 1b/2 combination therapy study of lifirafenib and mirdametinib in solid tumor patients with K-RAS mutations and other MAPK pathway aberrations. [Read the Full Post]
Network Indirect Comparison of 3 BRAF + MEK Inhibitors for the Treatment of Advanced BRAF Mutated Melanoma
87 views | Jun 12 2020
F Consoli et al. suggested a similar efficacy and a slightly different safety profile, related to specific molecular properties of the three different BRAF and MEK inhibitors currently approved in the management of advanced MM. [Read the Full Post]
